European review for medical and pharmacological sciences最新文献

{"title":"Decoding pharmacogenetics and metabolic panels in Jordanian women with polycystic ovary syndrome: a case-control study.","authors":"A Yehya, A M Rababa'h, J Hamadneh, C L Shaffer","doi":"10.26355/eurrev_202506_37276","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37276","url":null,"abstract":"<p><p>OBJECTIVE: This study aimed to assess the metabolic profiles and the frequency of the Serine/threonine kinase 11 (STK11) rs8111699 single-nucleotide polymorphism (SNP) among Jordanian women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS Ninety Jordanian women with PCOS and ninety healthy controls participated in the study. Metabolic characteristics were recorded, and direct sequencing was used to identify STK11 SNP genotypes. RESULTS: Among the PCOS patients, 23 (31.1%) had the wild-type (CC) genotype, while 39 (46.6%) and 28 (35.5%) had heterozygous (CG) and homozygous (GG) genotypes, respectively. There was no statistically significant difference in the genotype and allele distribution between the cases and controls (p=0.264 and p<0.702, respectively). Women carrying the minor G allele had poor metabolic profiles and more severe clinical features. CONCLUSIONS: The findings support the importance of early detection of PCOS, especially in high-risk populations, to enable timely preventive interventions. The interplay between genetic and metabolic profiles offers guidance for improving treatment outcomes in women with PCOS.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-14056.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"339-346"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra- and peri-meniscal polynucleotide injections for the treatment of symptomatic degenerative meniscus of the knee: 1-year findings from a prospective clinical trial.","authors":"G Anzillotti, P Conte, E M Bertolino, A Ferrero, B Di Matteo, M Vacca, M Di Martino, D Altomare, N Magarelli, E Lanza, P Verdonk, E Kon","doi":"10.26355/eurrev_202506_37273","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37273","url":null,"abstract":"<p><p>OBJECTIVE: Degenerative meniscal lesions consist of an alteration of the meniscal structure, eventually leading to pain and dysfunction. In the absence of mechanical symptoms, meniscectomy should be considered the last resort. Polynucleotides represent a novel treatment option which have shown promising results in different fields, including knee osteoarthritis. Hence, this study aimed to evaluate the safety and efficacy of a cycle of intra- and peri-meniscal polynucleotide injections for the treatment of degenerative meniscus. MATERIALS AND METHODS: This prospective study included 30 patients aged 25-65 with degenerative meniscal tears confirmed by MRI. Eligible patients were treated with three intra- and peri-meniscal injections of polynucleotides, administered with a two-week time interval under ultrasound guidance. The primary outcome was improvement in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) by at least 10 points from baseline to 12-month follow-up. Secondary outcomes included Visual Analog Scale (VAS) for pain, the International Knee Documentation Committee (IKDC) score, and the Tegner Activity Scale. Safety was assessed through the monitoring of adverse events. RESULTS: Twenty-four patients completed the 12-month follow-up. KOOS scores showed a statistically significant improvement from a mean of 61.99 at baseline to 84.32 at 12 months [95% CI: (79.25, 89.4); p<0.001]. VAS mm scores also decreased significantly, from 62.68 at baseline to 20.63 at 12 months [95% CI, (12.84, 28.41), p<0.001]. Improvements in IKDC and Tegner scores were observed but plateaued after 6 months. No adverse events were reported throughout the entire study period. CONCLUSIONS: A cycle of three intra- and peri-meniscal poly-nucleotides injections is able to provide statistically significant improvements in clinical scores up to 1 year of follow-up in patients affected by symptomatic degenerative meniscus of the knee.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"313-323"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective comparison of functional outcomes in open partial laryngectomy vs. total laryngectomyfor locally advanced (T3, T4) laryngeal cancer.","authors":"J Pies, S Hackenberg, M Scheich, T Meyer, A Scherzad, M Goncalves","doi":"10.26355/eurrev_202506_37271","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37271","url":null,"abstract":"<p><p>OBJECTIVE: Open partial laryngectomy (pLE), in cases not suited for transoral resection, aims to provide an oncologically safe resection, maintaining laryngeal function without the need for permanent tracheostomy. In cases requiring extensive resection, debate remains about whether pLE is feasible with a functional outcome or if total laryngectomy (tLE) is preferable. MATERIALS AND METHODS: This monocentric retrospective cohort study evaluated the resection of locally advanced (T3, T4) laryngeal carcinoma (LC) performed via open pLE or tLE between November 2010 and August 2023. Transoral resections, T1 and T2 cases were excluded. The presence of tracheostomy, the rate of oral feeding, the ability to phonate, and the oncologic outcome were assessed. RESULTS: The outcome of 38 pLEs and 56 tLEs was assessed. Adjuvant therapy was administered in 76% (n=29/38) pLEs and 47% (n=26/56) tLEs. While the oncologic results remained comparable between the two procedures (negative margins: p = 0.349; 5-year overall survival: p = 0.421), total laryngectomy (tLE) achieved better functional outcomes. Swallowing ability was markedly better after tLE (pLE vs. tLE: 39.5% vs. 91%, p < 0.001), particularly in patients with T4 tumors (pLE vs. tLE: 14% vs. 89%, p < 0.001) and in those over 65 years (pLE vs. tLE: 14% vs. 100%; p < 0.001). Overall, aspiration was the most frequent post-therapeutic complication after pLE, preventing unassisted oral intake in 58% of cases (22/38). The tracheostomy could be closed in 26% (n=10/38) of pLE-patients, at a median of 6.57 months (range 0.6-24 months). Consequently, after pLE 74% (n=28/38) of patients retained their tracheostomy at a median follow-up of 4 years. CONCLUSIONS: The low rates of tracheostoma closure, low rates of oral feeding over a median of 4 years, and R0 resection status of T4 tumors after pLE compared to tLE suggest patients with locally advanced LC are better suited for tLE.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-1.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"289-300"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Concern.","authors":"N Authors Listed","doi":"10.26355/eurrev_202506_37270","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37270","url":null,"abstract":"&lt;p&gt;&lt;p&gt;The Publisher, in agreement with the Editor-in-Chief, is issuing this Expression of Concern to inform readers that a formal investigation is currently underway regarding a set of published articles. Despite multiple attempts to contact the corresponding authors, we have not received any response to date. Further editorial actions, such as retraction or correction, will be taken as appropriate in due course. The articles under investigation fall into the following categories. These studies report extended follow-up periods, yet were published prior to the actual conclusion of the declared follow-up. This discrepancy raises serious concerns about the validity of the timeline and outcome reporting: Liao Y, Cheng S, Xiang J, Luo C. lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581. PMID: 29630113. Yao N, Sun JQ, Yu L, Ma L, Guo BQ. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4642-4649. doi: 10.26355/eurrev_201906_18043. PMID: 31210289. Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7399-7407. doi: 10.26355/eurrev_201909_18848. PMID: 31539127. Jiang J, Wu RH, Zhou HL, Li ZM, Kou D, Deng Z, Dong M, Chen LH. TGIF2 promotes cervical cancer metastasis by negatively regulating FCMR. Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):5953-5962. doi: 10.26355/eurrev_202006_21488. PMID: 32572908. These articles have been questioned as they appear to reuse identical or similar graphical elements and images from a shared library across multiple unrelated studies: Xu CF, Liu P, Tan J, Hu DF. Long noncoding RNA LINC00052 suppressed the proliferation, migration and invasion of glioma cells by upregulating KLF6. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4822-4827. doi: 10.26355/eurrev_201906_18068. PMID: 31210314. Zheng FX, Wang XQ, Zheng WX, Zhao J. Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4793-4799. doi: 10.26355/eurrev_201906_18064. PMID: 31210310. Liao J, Xie N. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1087-1092. doi: 10.26355/eurrev_201902_16998. PMID: 30779076. Lu J, Xu FQ, Guo JJ, Lin PL, Meng Z, Hu LG, Li J, Li D, Lu XH, An Y. Long noncoding RNA GAS5 attenuates cardiac fibroblast proliferation in atrial fibrillation via repressing ALK5. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7605-7610. doi: 10.26355/eurrev_201909_18883. PMID: 31539152. Shi JQ, Wang B, Cao XQ, Wang YX, Cheng X, Jia CL, Wen","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"287-288"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring nutraceutical solutions for prediabetes: a narrative review on the effects of banaba and chromium picolinate.","authors":"G Derosa, P Maffioli, A D'Angelo, V Foscaldi, R Piazza, M Mangrella, F Fogacci, A F G Cicero","doi":"10.26355/eurrev_202506_37275","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37275","url":null,"abstract":"<p><p>Prediabetes is an intermediary metabolic state marked by impaired glucose control, often preceding the development of type 2 diabetes (T2D). Early detection of prediabetes and intervention are critical to prevent the progression to T2D and its associated complications. This review examines the effects of nutraceuticals on regulating metabolism, with a focus on glucose control, specifically chromium picolinate (CrP) and banaba leaf extract. CrP has been extensively studied, and its role in regulating metabolism has been officially recognized. Preclinical research demonstrates its ability to improve glucose control by enhancing insulin sensitivity. These effects explain the reductions in fasting plasma glucose, elevated hemoglobin A1c, and insulin levels observed in clinical studies, particularly in patients with T2D. Banaba (Lagerstroemia speciosa) leaf extract, rich in corosolic acid and ellagitannins, has also shown promising results in improving glycemic control. As observed in preclinical studies, both banaba extract and corosolic acid exert insulin-sensitizing, glucose-lowering, and lipid-lowering properties. Clinical trials have confirmed these effects in individuals with T2D and prediabetes. Based on this evidence, combining CrP and banaba leaf extract may offer synergistic benefits in managing dysglycemia and delaying the onset of T2D in individuals with prediabetes. Only one study has evaluated the effects of the CrP and banaba extract combination, showing positive outcomes in individuals with prediabetes. Further research is needed to corroborate these preliminary findings. In conclusion, nutraceuticals like CrP and banaba leaf extract hold promise as complementary therapies to be used alongside lifestyle modifications for individuals with prediabetes.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-1-1-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"324-338"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic role of miR-190, miR-221, and miR-381 in breast cancer: a systematic review and meta-analysis.","authors":"S Matsas, A Ruiz Simões, P Nazareth Aguiar, Y Abdou, H Krontiras, A Del Giglio","doi":"10.26355/eurrev_202506_37272","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37272","url":null,"abstract":"<p><p>OBJECTIVE: Breast cancer is the most frequently diagnosed malignancy in women and a leading cause of cancer-related mortality. Conventional prognostic tools may not fully capture disease outcomes. MicroRNA (miR) expression has emerged as a potential prognostic factor, though findings remain inconsistent. This systematic review and meta-analysis assess the prognostic role of miR-190, miR-221, and miR-381 in predicting overall survival (OS) among breast cancer patients. MATERIALS AND METHODS: A comprehensive literature search in PubMed, Embase, and Scopus identified relevant studies. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the relationship between miR expression and OS. Subgroup analyses were conducted to explore potential sources of heterogeneity. RESULTS: Four studies on miR-221, four on miR-190, and three on miR-381 met inclusion criteria. High miR-190 expression was significantly associated with improved OS (HR: 0.63; 95% CI: 0.47-0.84), as was miR-381 (HR: 0.64; 95% CI: 0.52-0.79). No significant association was found between miR-221 expression and OS (HR: 1.12; 95% CI: 0.86-1.46). Subgroup analysis reinforced these findings, and Newcastle-Ottawa scale assessment indicated low publication bias in 10 out of 11. CONCLUSIONS: Elevated miR-190 and miR-381 levels are associated with improved OS in breast cancer, whereas the prognostic role of miR-221 remains unclear. These findings underscore the potential of miR-190 and miR-381 as prognostic biomarkers.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-18-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"301-312"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain morphology alterations in adult males with stuttering disorder in Saudi Arabia: a pilot study.","authors":"M Alqarni, A Abujamea, A Almudhi, S Bashir","doi":"10.26355/eurrev_202505_37226","DOIUrl":"https://doi.org/10.26355/eurrev_202505_37226","url":null,"abstract":"<p><p>OBJECTIVE: The neurophysiological and neuroanatomical alterations underlying brain morphology in adult males who stutter remain insufficiently understood. This study aimed to determine whether individuals who stutter exhibit structural differences in frontal brain regions associated with somatosensory and motor systems critical for speech production. MATERIALS AND METHODS: The study protocol was approved by the Institutional Review Board of King Saud University (KSU). A total of 54 adult male participants [27 stutterers (ST) and 27 non-stutterers (NST)], aged 18-55 years, were enrolled. A certified speech-language pathologist assessed all participants using the validated Stuttering Severity Instrument-4 (SSI-4). High-resolution T1-weighted magnetic resonance imaging (MRI) scans (SAG T1 3D MP-RAGE sequence) were acquired using a Siemens Skyra 3.0T scanner at the Department of Medical Imaging, KSU Medical City, Riyadh. RESULTS: Compared to NST participants, individuals in the ST group showed significant volumetric alterations in the left precentral gyrus, right superior frontal gyrus, and right middle frontal gyrus. Additional significant differences were observed in the left middle frontal gyrus, left inferior frontal gyrus pars opercularis, left inferior frontal gyrus pars triangularis, left inferior frontal gyrus, left precuneus, left pole of the superior temporal white matter, and left insular cortex. These regions demonstrated consistent structural differences between ST and NST participants, suggesting a robust association between stuttering and abnormal morphology in frontal and related cortical areas. CONCLUSIONS: These findings provide evidence of structural abnormalities in frontal brain regions implicated in the regulation of somatosensory and motor processes essential for speech production. This supports the hypothesis that stuttering is associated with disrupted neuroanatomical organization in key speech-related cortical networks.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-17.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 5","pages":"278-286"},"PeriodicalIF":3.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction note: Effect of exosome-carried miR-30a on myocardial apoptosis in myocardial ischemia-reperfusion injury rats through regulating autophagy.","authors":"Y-Q Xu, Y Xu, S-H Wang","doi":"10.26355/eurrev_202505_37233","DOIUrl":"https://doi.org/10.26355/eurrev_202505_37233","url":null,"abstract":"<p><p>The article \"Effect of exosome-carried miR-30a on myocardial apoptosis in myocardial ischemia-reperfusion injury rats through regulating autophagy\" by Y.-Q. Xu, Y. Xu, S.-H. Wang, published in Eur Rev Med Pharmacol Sci 2019; 23 (16): 7066-7072-DOI: 10.26355/eurrev_201908_18748-PMID: 31486507 has been retracted in accordance with the Publisher and the Editor in Chief. Following some concerns raised by a third party regarding possible overlaps and duplication in the Figures, the journal has started an investigation to assess the validity of the concerns, as well as a possible Figure manipulation. The journal's investigation revealed a duplication between panels Model and miR-30a inhibitor of Figure 1. Therefore, the manuscript is retracted due to figure duplication. The journal has contacted the authors to inform them of the ongoing investigation and to request the original data supporting the manuscript; however, the authors have not responded to these communications. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18748.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 5","pages":"224"},"PeriodicalIF":3.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inadvertent sub-macular triamcinolone during pars plana vitrectomy for epiretinal membrane: A case report.","authors":"T Erakgün, H H Gobeka","doi":"10.26355/eurrev_202505_37221","DOIUrl":"https://doi.org/10.26355/eurrev_202505_37221","url":null,"abstract":"<p><p>BACKGROUND: The study aims to describe an inadvertent sub-macular triamcinolone acetonide (TA) deposition following a TA-assisted pars plana vitrectomy (PPV) for epiretinal membrane (ERM) peeling. CASE REPORT: In this interventional case report, a 75-year-old female with ERM-induced visual distortion underwent TA-assisted 25-gauge three-port PPV, endolaser photocoagulation, and sulfur hexafluoride (SF6) gas (8%) endo tamponade to treat ERM in the left eye. Significant TA deposition was observed intraoperatively in the submacular region, which remained after ERM and internal limiting membrane (ILM) removal. One month after PPV, the retina appeared flat, with no significant vitreoretinal interface defects or macular ultrastructural abnormalities. Vision improved from 0.40 to 0.2 logMAR, and there was no evidence of any ophthalmoscopic damage. CONCLUSIONS: Inadvertent sub-macular TA deposition following ERM peeling did not cause any significant surgical sequelae.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-13.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 5","pages":"225-230"},"PeriodicalIF":3.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients.","authors":"Q-F Xu, Y-X Tang, X Wang","doi":"10.26355/eurrev_202505_37229","DOIUrl":"https://doi.org/10.26355/eurrev_202505_37229","url":null,"abstract":"<p><p>The article \"LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients\" by Q.-F. Xu, Y.-X. Tang, X. Wang published in Eur Rev Med Pharmacol Sci 2018; 22 (14): 4440-4447-DOI: 10.26355/eurrev_201807_15495-PMID: 30058681 has been retracted in accordance with the Publisher and the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/4756B8806339A2FA95E3A77A3FB451), the journal has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation identified a discrepancy between the data described in the text and the content presented in Figure 1, raising concerns about the originality and accuracy of the data. Additionally, detailed information regarding Ethics Approval was missing. The authors have been notified about the ongoing investigation and were asked to provide the original data, however, they have not responded to these communications. As a result, due to unresolved concerns regarding data integrity, lack of ethical approval documentation, and the authors' failure to respond to repeated requests for clarification, the article has been retracted. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15495.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 5","pages":"222"},"PeriodicalIF":3.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}